Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

NCT00113048 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: CAMPATH (alemtuzumab)

Sponsor

Genzyme, a Sanofi Company